These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 540347)

  • 41. [Studies on the problem of schizophrenia. IV. Distribution of C-14-radioactive lysergic acid diethylamide (C-14-LSD 25) in the animal organism].
    ARNOLD OH; HOFMANN G; LEUPOLD-LOWENTHAL H
    Wien Z Nervenheilkd Grenzgeb; 1958; 15(1-4):15-27. PubMed ID: 13604283
    [No Abstract]   [Full Text] [Related]  

  • 42. Psychotomimetic drugs; chemical and pharmacological aspects.
    HOFMANN A
    Acta Physiol Pharmacol Neerl; 1959 Jun; 8():240-58. PubMed ID: 13852489
    [No Abstract]   [Full Text] [Related]  

  • 43. [Protective action of lysergic acid ethylamide (LAE-32) on behavior changes & on histological lesions of the central nervous system induced in mice by chronic treatment with 5-hydroxytryptamine].
    SORIANI S; FAVALE E
    Sist Nerv; 1959; 11(1):13-21. PubMed ID: 13659105
    [No Abstract]   [Full Text] [Related]  

  • 44. [First experiments in hemicrania and epilepsy with 1-methyl-lysergic acid butanolamide, a substance with antiserotonin effects].
    SICUTERI F
    Prog Med (Napoli); 1960 Jan; 16():20-2. PubMed ID: 14446409
    [No Abstract]   [Full Text] [Related]  

  • 45. N1-methyl-2-125I-lysergic acid diethylamide, a preferred ligand for in vitro and in vivo characterization of serotonin receptors.
    Hoffman BJ; Scheffel U; Lever JR; Karpa MD; Hartig PR
    J Neurochem; 1987 Jan; 48(1):115-24. PubMed ID: 3794694
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Evaluation of UML-491 in the treatment of vascular headaches. An analysis of the effects of 1-methyl-D-lysergic acid (plus) butanolamide bimaleate (methysergide).
    FRIEDMAN AP; LOSIN S
    Arch Neurol; 1961 Mar; 4():241-5. PubMed ID: 13701987
    [No Abstract]   [Full Text] [Related]  

  • 47. Antagonism between an antiserotonin-the butanolamide of 1-methyl-lysergic acid--and the effects of a histamine-liberating substance 48/80 B. W. in man.
    SICUTERI F; MICHELACCI S; FRANCHI G
    Int Arch Allergy Appl Immunol; 1959; 15():291-9. PubMed ID: 14446403
    [No Abstract]   [Full Text] [Related]  

  • 48. [Effect of monoethylamide (LAE) and diethylamide (LSD) of lysergic acid on behavior of mouse with imino-beta, beta-dipropionitrile induced circular movement].
    WIDLOCHER D; NAKAJIMA H; THUILLIER J
    C R Seances Soc Biol Fil; 1957; 151(4):668-70. PubMed ID: 13489946
    [No Abstract]   [Full Text] [Related]  

  • 49. Relationships between chemical structure and psychoses with the use of psychotoxic substances; comparative pharmacopsychiatric analysis: a new research method.
    SOLMS H
    J Clin Exp Psychopathol; 1956; 17(4):429-33. PubMed ID: 13406032
    [No Abstract]   [Full Text] [Related]  

  • 50. Treatment of autistic schizophrenic children with LSD-25 and UML-491.
    BENDER L; GOLDSCHMIDT L; SANKAR DV
    Recent Adv Biol Psychiatry; 1961; 4():170-9. PubMed ID: 13867084
    [No Abstract]   [Full Text] [Related]  

  • 51. N1-methyl-2-[125I]LSD ([125I]MIL), a preferred ligand for serotonin 5-HT2 receptors.
    Hoffman BJ; Karpa MD; Lever JR; Hartig PR
    Eur J Pharmacol; 1985 Mar; 110(1):147-8. PubMed ID: 4007051
    [No Abstract]   [Full Text] [Related]  

  • 52. The anti-tumor action of lysergic acid derivatives and their serotonin-blocking effect as reflected by the I 131 distribution in rats.
    SCOTT KG; STONE RS
    Cancer Res; 1959 Aug; 19():783-7. PubMed ID: 14444248
    [No Abstract]   [Full Text] [Related]  

  • 53. The effect of lysergic acid diethylamide, 5-hydroxytryptamine, and related compounds on the liver fluke, Fasciola hepatica.
    MANSOUR TE
    Br J Pharmacol Chemother; 1957 Dec; 12(4):406-9. PubMed ID: 13489165
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Active transport of lysergic acid diethylamide.
    Wright EM
    Nature; 1972 Nov; 240(5375):53-4. PubMed ID: 4570642
    [No Abstract]   [Full Text] [Related]  

  • 55. QSAR of agents involved in serotonin and LSD binding sites.
    Chan YL; Lien EJ; Shih JC
    NIDA Res Monogr; 1978; (22):103-13. PubMed ID: 30904
    [No Abstract]   [Full Text] [Related]  

  • 56. Displacement of specific serotonin and lysergic acid diethylamide binding by Ergalgin, a new antiserotonin drug.
    Oelszner W
    Acta Biol Med Ger; 1980; 39(8-9):897-901. PubMed ID: 7282219
    [TBL] [Abstract][Full Text] [Related]  

  • 57. [Pharmacological trials concerning the mechanism of convulsions due to pure oxygen under pressure in mice].
    LABORIT H; BROUSSOLLE B; PERRIMOND-TROUCHET R
    J Physiol (Paris); 1957 Nov; 49(5):953-62. PubMed ID: 13514634
    [No Abstract]   [Full Text] [Related]  

  • 58. The dopamine receptor: differential binding of d-LSD and related agents to agonist and antagonist states.
    Creese I; Burt DR; Synder SH
    Life Sci; 1975 Dec; 17(11):1715-9. PubMed ID: 1207384
    [No Abstract]   [Full Text] [Related]  

  • 59. Reversal learning enhanced by lysergic acid diethylamide (LSD): concomitant rise in brain 5-hydroxytryptamine levels.
    King AR; Martin IL; Melville KA
    Br J Pharmacol; 1974 Nov; 52(3):419-26. PubMed ID: 4458849
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Separation of D-lysergic acid diethylamide derivatives using micellar electrokinetic capillary chromatography.
    Djordjevic MN; Fitzpatrick F; Houdiere F
    Electrophoresis; 2000 Mar; 21(4):724-8. PubMed ID: 10733212
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.